Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13874912 | 1.00 | DPP4 (0.40) | DPP4HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL12568612 | 1.00 | DPP4 (0.40) | DPP4HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL13874697 | 0.98 | HRH3 (0.39) | DPP4HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL12568611 | 0.98 | HRH3 (0.39) | DPP4HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL9927936 | 0.98 | HRH3 (0.39) | DPP4HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL9927914 | 0.90 | KDM2B (0.37) | DPP4L3MBTL3L3MBTL1 | |
| SCHEMBL12568610 | 0.90 | KDM2B (0.37) | DPP4L3MBTL3L3MBTL1 | |
| SCHEMBL9927928 | 0.88 | KDM2B (0.38) | DPP4HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL12568609 | 0.88 | KDM2B (0.38) | DPP4HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL13874479 | 0.85 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-1953165-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | DPP4 3114/4885HRH3 2984/4885KCNH2 416/4885 |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | DPP4 3114/4885HRH3 2984/4885KCNH2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.